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Abstract 
In pharmaceutical research, assessing drug candidates’ odds of success as they move through clinical 
research often relies on crude methods based on historical data. However, the rapid progress of 
machine learning offers a new tool to identify the more promising projects. To evaluate its usefulness, 
we trained and validated several machine learning algorithms on a large database of projects. Using 
various project descriptors as input data we were able to predict the clinical success and failure rates 
of projects with an average balanced accuracy of 83% to 89%, which compares favorably with the 56% 
to 70% balanced accuracy of the method based on historical data. We also identified the variables that 
contributed most to trial success and used the algorithm to predict the success (or failure) of assets 
currently in the industry pipeline. We conclude by discussing how pharmaceutical companies can use 
such model to improve the quantity and quality of their new drugs, and how the broad adoption of 
this technology could reduce the industry’s risk profile with important consequences for industry 
structure, R&D investment, and the cost of innovation 
 
 
 
 
 
 
 
 
 
 
We thank Evaluate Ltd. for giving us access to the EvaluatePharma® data used in this study and for their 
valuable feedback. The views expressed in this work are those of the authors. Prof. Riccaboni and Mr. Munos 
have been members of the Evaluate Ltd. “Forecasting Advisory Board” 2018-2019. 
Machine learning (ML) tools are used with growing success across industries to improve decision-making. 
Businesses that have access to large volumes of high-quality data are increasingly turning to ML to perform tasks 
where it surpasses humans. From forecasting demand, resource needs, or financial performance; to predicting 
failure, detecting fraud, automating processes, reading X-rays; designing molecules; or understanding customer 
behavior, there is hardly a facet of business that cannot benefit from ML1. In the pharmaceutical industry, which 
spends more than $180 billion annually in research and development (R&D)2 but faces failure rates that often 
exceed 90%3, a model that could predict the outcomes of clinical research phases would be particularly valuable. 
Several pioneering contributions have already used ML to mine clinical trials data in order to predict the 
likelihood of trial success and regulatory approval for drug candidates4,5,6. Our paper extends this work by 
recognizing that clinical and regulatory success depend upon the complex interaction of a broad set of predictors 
that includes both trial-related variables as well as other success factors such as molecule attributes, regulatory 
status, patent protection, company features, and market data. To model these complex dynamics, we applied 
eight ML approaches to our data, which produced a best-performing algorithm (BART) that has never been used 
in this context. We also identified new, highly relevant predictors of success. 
Section 2 below describes our ML methodology and dataset. Section 3 compares the performance of our “best-
in-class” ML algorithm to the methods commonly used in industry. Section 4 illustrates one use of our ML 
approach by predicting the outcomes of the current industry pipeline. We conclude by summarizing our findings 
and discussing their potential implications for the pharmaceutical industry and biomedical research. 
 
  
2. Data and Methods 
 
Box 1 | Machine Learning  
Learning computer algorithms, that evaluate and automatically improve their performance, go back many 
decades. In 1952 Arthur Samuel designed one of the first computer learning programs that improved its ability 
to play checkers by learning from previous moves. He coined the term “machine learning” (ML), which has come 
to designate a computer algorithm that `learns’ to better its performance on a specific task. Since the 1950s 
machine learning has made huge advances that have heightened its performance and broadened its appeal. 
Image recognition software, email filters, and personalized advertisement are just some of the applications which 
rely on ML technology. And thanks to the growing availability of large datasets, machine-learning is making its 
way into healthcare, including drug discovery7, medical imaging8, and health monitoring8. 
A simple three-step machine-learning routine is depicted in Exhibit 1. An input dataset for which the outcome of 
interest is known, is randomly split into two subsets (step 1): a training set and a validation set. During the 
learning process the ML algorithm repeatedly evaluates pairs of input/output data from the training set (step 2). 
For each pair, it estimates an output value, and compares it to the true (known) value. The distance between the 
two is then used by the algorithm to fine-tune itself and improve its performance. As the training progresses, 
that distance shrinks, until it is consistently smaller than a pre-set value. At that point, the algorithm is deemed 
to be trained. (Note: if the input data do not have enough explanatory power, the training may fail, which is a 
signal that another, more accurate model is needed.) 
Once it is trained, the algorithm is validated by applying it to the validation set – which it has never seen (step 3). 
To be successfully validated, it must estimate the output values of the validation set with an accuracy that is 
sufficient for its purpose. (Note: It is possible for the algorithm to fail the validation step. This can happen, for 
instance, when the input dataset is too small, causing the algorithm to “over-learn” the results, instead of 
predicting them.) 
When the output data is binary (e.g. pass/fail) the performance of the algorithm can be summarized by a 
“confusion matrix” which relates classified successes and failures to true successes and failures. From the entries 
of the confusion matrix various performance measures can be derived that summarize the goodness-of-fit of the 
classification (see template in Exhibit 2). In this paper, we focus particularly on the area under the receiver 
operating curve (AUC)9 and balanced accuracy (BACC) which are widely used to assess the performance of 
classifiers. 
After successful validation, the algorithm can be applied to similar, new input data and used to predict their 
(unknown) output. The great advantage of ML over traditional statistical methods such as regression or 
discriminant analyses, is that ML excels at modeling non-linear relationships (e.g., synergies and multiple 
feedback loops). Given such data, its performance is consistently better, as our example will illustrate. 
 
Exhibit 1:Example of a supervised machine learning routine 
 
 
 
Exhibit 2:Confusion matrix template including performance measures 
 Actual success Actual failure  
Classified 
as success 
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 ∑ 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 
𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 (𝑃𝑃𝑉)
=
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠.
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠. + ∑ 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠.
 
Classified 
as failure 
∑ 𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 ∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 
𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑣𝑒 𝑣𝑎𝑙𝑢𝑒 (𝑁𝑃𝑉)
=
∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔.
∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔. + ∑ 𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑔.
 
 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦(𝑆𝐸𝑁𝑆)
=
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠.
∑ 𝑇𝑟𝑢𝑒 𝑝𝑜𝑠. + ∑ 𝐹𝑎𝑙𝑠𝑒 𝑛𝑒𝑔.
 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦(𝑆𝑃𝐸𝐶)
=
∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔.
∑ 𝑇𝑟𝑢𝑒 𝑛𝑒𝑔. + ∑ 𝐹𝑎𝑙𝑠𝑒 𝑝𝑜𝑠.
 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (𝐴𝐶𝐶)
=
∑𝑇𝑟𝑢𝑒 𝑝𝑜𝑠. +∑𝑇𝑟𝑢𝑒 𝑛𝑒𝑔.
𝐴𝑙𝑙 𝑜𝑢𝑡𝑐𝑜𝑚𝑒𝑠
 
𝐵𝑎𝑙𝑎𝑛𝑐𝑒𝑑 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (𝐵𝐴𝐶𝐶) = (𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 +  𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦)/2 
 
Area under the receiver operating curve (AUC): The closer to one 
the better the model solves the trade-off between SENS and SPEC. 
𝐹1 𝑆𝑐𝑜𝑟𝑒 (𝐹1)
=
2(𝑆𝐸𝑁𝑆 ∗ 𝑃𝑃𝑉)
𝑆𝐸𝑁𝑆 + 𝑃𝑃𝑉
 
 
We trained various algorithms on a database of drug development projects to predict the success or failure of 
the clinical research phases in which they were engaged. Each project is a combination of input and output data. 
The input data recapitulates the attributes of each project -- e.g., the features of the molecule; intended market; 
company; etc. – while the output data indicates the status of its most advanced clinical research phase – e.g., 
success, failure, or on-going. For instance, a project might be lorlatinib to treat ALK positive, non-small cell lung 
cancer. The input data would describe a small molecule developed by Pfizer that was granted expedited FDA 
reviewa (see Exhibit 10 in the supplementary material A.1 for a detailed description of all features). The output 
data would indicate: ”NDA/BLA & Approved or Marketed”b. 
Our data comes from a novel database created by Evaluate Ltd. to which we were granted accessc.  It includes 
8,785 projects that were undertaken in the United States during the last decade. They encompass more than 
4,500 NMEs and 1,300 companies and cover a wide range of indications. The anonymized dataset can be 
downloaded from supplementary material B, which includes a link to the executable R code. 
The database was partitioned into three subsets (PI, PII, and PIII), for projects having reached phase I, II, and III 
respectively. For each subset, we randomly split the projects for which the outcome is known (i.e. failure or 
success) into a training and a validation set. Exhibit 3 shows the grid used to ascertain the output value of each 
project. It also shows the clinical success rates achieved for each phase by the molecules in our sample. Before 
training the ML algorithms, we evaluated different pre-processing techniques such as feature selection methods 
and various ways to deal with missing information. 
After preprocessing, the training sets were used to train eight different ML algorithms: Bayesian additive 
regression tree (BART), random forest (RF), boosted decision trees (C5.0), support vector machine (SVM), 
 
a Projects given expedited FDA review are projects that have received one of the following FDA designations: priority 
review, breakthrough therapy, accelerated approval, or fast track. 
b We pooled projects that reached NDA/BLA with Approved and Marketed ones since it is rare that projects fail during 
NDA/BLA review. (In our data only 2.6% fail during NDA/BLA review, and 0.1% are not marketed even though approved), 
which results in too few observations to successfully train ML algorithms. 
c Evaluate Ltd. is a commercial company that collects and integrates company-reported and other published 
pharmaceutical product and financial information to create the EvaluatePharma® database, which includes company 
pipelines, sales forecasts and proprietary analytics. 
probabilistic regression (PROBIT), artificial neural net (ANN), a simple decision tree (DT) and an ensemble learner, 
which were then applied to their respective validation sets. The results were compared using several 
performance metrics such as the area under the curve (AUC) and balanced accuracy (BACC, see Exhibit 2). The 
best performing algorithm across data sets – PI, PII and PIII – was referred to as “best-in-class”. Details about the 
pre-processing step and the training of the eight algorithms can be found in the supplementary material A.2. 
In the next section, the “best-in-class” algorithm is compared to two common prediction methods – one based 
on historical data, and the other on discriminant analysis, which is frequently used to classify binary outcomes 
(success/failure). 
Exhibit 3:Project status classification and number of projects for each clinical research phase 
 Data sets according to clinical research phases 
Project status Phase I Phase II Phase III 
NDA/BLA & Approved or Marketed Success 498 Success 499 Success 579 
Phase III, on-going Success 336 Success 347 On-going 559 
Phase III, abandoned/suspended Success 248 Success 147 Failure 290 
Phase II, on-going Success 844 On-going 2372  
Phase II, abandoned/suspended Success 735 Failure 1794  
Phase I, on-going On-going 1858   
Phase I, abandoned/suspended Failure 1231   
Total number of projects by phase* 5750 5159 1428 
Avg. success rate (success/ sum) 68.4% 35.7% 66.6% 
Projects that refer to combined phases are assigned to the earlier phase (e.g. phase2/3 is assigned to phase 2). The same 
project can be assigned to more than one dataset. For instance, a phase III project can be categorized as on-going in PIII, and 
successful in PI and PII. The total number of distinct projects as found in the database is 8785. Projects that have succeeded in 
phase III have been lumped into a “NDA/BLA & Approved or Marketed” category, as there were too few NDA/BLA projects to 
train algorithms, if that category was split out. (In our data only 2.6% fail between NDA/BLA and approval and 0.1% are not 
marketed even though approved), which results in too few observations to successfully train ML algorithms). 
 
  
3. Machine learning vs. common estimation methods 
 
The Bayesian Additive Regression Tree (BART) method10 produced the best-performing algorithm for each 
dataset across to various performance measures (Exhibit 16 in the supplementary material A.2 contains the 
performance measures of each method on each data set). To add perspective, this section compares the BART 
results to the cruder method based on historic success rates and to discriminant analysis. 
The historical (HIST) method classifies projects as successful if the historic success rate for compounds targeting 
the same indication in the same phase is greater than 50%. The discriminant analysis (DISCR) is an adaptation of 
regression analysis to situations in which the dependent variable is qualitative (e.g., success vs. failures). 
The results of this comparison are reported in Exhibit 4 which displays the average performance measures on 
the validation sets obtained from resampling randomly training and validation sets 100 times. They show that 
the `best-in-class’, BART algorithm classifies the outcomes of clinical research phases (e.g., success or failures) 
with a balanced accuracy of at least 83% (PI = 83%; PII = 89%; PIII = 86%). The AUC reaches 93%, 96%, and 94% 
for PI, PII and PIII respectively. The HIST method is markedly less accurate (BACC: PI = 56%; PII = 60%; PIII = 70%, 
AUC: PI=64%, PII=69%, PIII=79%). The DISCR performs better than HIST but is still significantly less accurate than 
the BART ML approach (BACC: PI = 73%; PII = 78%; PIII = 73%, AUC: PI=85%, PII=88%, PIII=84%). 
 
Exhibit 4:Comparative performance of `best-in-class' BART ML, historical method, and discriminant analysis 
ML 
Method 
Data 
set 
AUC 
Mean 
AUCL 
Mean 
AUCH 
Mean 
SENS 
Mean 
SPEC 
Mean 
PPV 
Mean 
NPV 
Mean 
F1 
Mean 
BACC 
Mean 
BART 
PI 0.93 0.92 0.95 0.91 0.76 0.89 0.80 0.90 0.83 
PII 0.96 0.95 0.97 0.82 0.95 0.90 0.91 0.86 0.89 
PIII 0.94 0.92 0.97 0.88 0.84 0.92 0.78 0.90 0.86 
HIST 
PI 0.64 0.60 0.67 0.83 0.29 0.71 0.45 0.77 0.56 
PII 0.69 0.65 0.74 0.26 0.94 0.70 0.71 0.38 0.60 
PIII 0.79 0.73 0.86 0.71 0.70 0.82 0.55 0.76 0.70 
DISCR 
PI 0.85 0.79 0.85 0.89 0.56 0.82 0.71 0.85 0.73 
PII 0.88 0.84 0.90 0.65 0.91 0.79 0.83 0.71 0.78 
PIII 0.84 0.75 0.88 0.87 0.60 0.82 0.69 0.84 0.73 
Performance values are averaged over 100 repetitions for which the training/validation routine is performed. Abbreviations: 
AUC - Area under the receiver operating characteristic curve; AUCL(H) - Lower (Upper) 95% AUC confidence interval 
calculated for each repetition based on DeLong method11; SENS: Sensitivity; SPEC: Specificity; PPV: Positive predictive value, 
NPV: Negative predictive value; F1: F1 Score; BACC: Balanced accuracy. 
 
The differences between the ML and HIST methods are visualized in Exhibit 5. Across clinical phases, ML-
predicted successes and failures appear more representative of their actual distributions than the predictions 
based on historic success rates. The same is true of the mean classification value (see Exhibit 23 in the 
supplementary material A.4 for a comparison between ML and DISCR). 
 
Exhibit 5:Best-in-class ML and historical classification values separated by phase and true outcome 
The Exhibit shows for each phase the estimated success probabilities for failed and successful projects in the validation set 
using the BART method (red dots) and the historical method (grey dots). For each method, the estimated average success 
probability is depicted by horizontal lines. On average, the estimated success probability of successful (failed) projects is 
higher (lower) with BART than HIST.  
 
The better performance of the BART algorithm relative to discriminant analysis derives from its ability to handle 
missing information in the input dataset12; to include features based on their contribution to performance13; and 
to exploit hidden relations between project features. Analyzing the features that are most prominently selected 
during the training phase can point us to the kind of information is useful to boost predictive performance. We 
found that the features most frequently selected by the algorithm across phases relate to company, product, 
market and regulatory status. Exhibit 6 shows that information on company, indication, market, and mode of 
action (MoA) success rates as well as clinical trial costs, patent duration and expedited FDA review is frequently 
selected by the algorithm and interactions across features are commond.  
Having successfully trained and validated an ML algorithm, the next section will apply it to predict the outcome 
of the projects in the industry pipeline, i.e., those whose clinical research status was classified as on-going in our 
sample. To mitigate the potential bias from missing data we pre-processed the data using a nearest neighbor 
algorithm. 
 
  
 
d In addition, in Exhibit 18 of the supplementary material A.2, we report the features selected by the backward/forward 
probabilistic regression used in DISCR together with its coefficients, standard errors and p-values. It provides a notion of the 
direction of effects and their significance. Note that the selected features overlap with the ones selected by BART, yet DISCR 
imposes by construction a linear model, not allowing feature interactions. 
 
Exhibit 6: Most relevant features in `best-in-class’ algorithm 
The Exhibit shows the top ranked features based on how frequently they were selected by BART. The BART tree inclusion 
proportion (IP) denotes the average fraction of times a feature was selected in a tree. The variable interaction count (VIC) 
sums how many times features were selected in consecutive nodes across BART trees. The higher the value of IP (VIC), the 
more relevant is the feature (feature combination) for classifying outcomes. For computational purposes it is the difference 
between the features’ IPs and VICs, not their absolute values, that matters. The features are color coded based on their 
category: product features (orange), market features (blue), company features (pink), regulatory and other features (green). 
We abbreviate success ratio with s.r. 
 
 
 
 
 
 Feature Importance by singular features 
Rank 
based 
on IP 
PI PII PIII 
 Feature  IP  Feature  IP  Feature  IP  
1 Phase s.r. by MoA 0.040 Clinical trial cost 0.047 Company s.r. 0.047 
2 Phase s.r. by indication 0.038 Phase s.r. by indication 0.042 Phase s.r. by indication 0.047 
3 Company s.r. 0.038 Company s.r. 0.042 Phase s.r. by MoA 0.045 
4 Clinical trial cost 0.037 Patent Duration 0.040 Clinical trial cost 0.044 
5 Market s.r. 0.036 Market s.r. 0.039 
Clinical trial results: 
Negative 
0.041 
6 Therapy type: Unclassified 0.033 Phase s.r. by MoA 0.038 Product Failed: No 0.032 
7 R&D (Count) 0.031 Product Failed: Yes 0.033 Expedited status: Yes 0.030 
8 Expedited status: No 0.030 Expedited status: Yes 0.032 Product Failed: Yes 0.029 
9 Expedited status: Yes 0.030 Expedited status: No 0.030 Patent Duration 0.029 
10 Product Failed: No 0.026 Product Failed: No 0.028 Expedited status: No 0.027 
 Feature importance by feature interactions 
Rank 
based 
on VIC 
PI PII PIII 
Feature A Feature B VIC Feature A Feature B VIC Feature A Feature B VIC 
1 
Clinical trial 
cost 
Phase s.r.by 
indication 
463 
Clinical trial 
cost 
Company s.r. 
693 
 
Phase s.r.by 
indication 
Company s.r. 
211 
 
2 
Company 
Listed: Yes 
Market s.r. 408 Company s.r. R&D (Count) 
352 
 
Phase  s.r.by 
MoA 
Phase s.r.by 
indication 
202 
 
3 
Therapy type: 
Unclassified 
R&D 
(Count) 
280 
Patent 
duration 
Company s.r. 
338 
 
Clinical trial 
results: 
Negative 
Clinical trial 
cost 
174 
 
4 
Therapy type: 
Monotherapy 
R&D 
(Count) 
257 
Phase  s.r.by 
MoA 
Phase  s.r.by 
MoA 
334 
 
Phase s.r.by 
MoA 
Company s.r. 
161 
 
5 
Phase s.r.by 
indication 
Company 
s.r. 
248 
Clinical trial 
cost 
Phase  s.r.by 
MoA 
315 
 
Product 
Failed: No 
Phase s.r.by 
MoA 
154 
 
6 Company s.r. 
R&D 
(Count) 
230 
Phase  s.r.by 
indication 
Company s.r. 297 
Clinical trial 
cost 
Company s.r. 
137 
 
7 
Clinical trial 
cost 
Clinical trial 
cost 
226 Company s.r. 
Time in 
market 
285 Company s.r. R&D Cost 
130 
 
8 
Phase s.r.by 
indication 
R&D 
(Count) 
216 
Phase  s.r.by 
MoA 
Company s.r. 
281 
 
Product 
Failed: Yes 
Company s.r. 
123 
 
9 
Phase s.r.by 
MoA 
Patents cite 214 
Clinical trial 
cost 
Company s.r. 
269 
 
Expedited 
status: Yes 
Phase s.r.by 
MoA 
114 
 
10 
Phase s.r.by 
MoA 
Company 
s.r. 
211 
Time in 
Phase 
Clinical trial 
cost 
259 
Expedited 
status: Yes 
Phase s.r.by 
indication 
111 
 
4. Predicting the outcome of compounds in the industry pipeline 
 
Our project database contained 4,789 projects engaged in various phases of clinical research  
(PI = 1,858; PII = 2,372; PIII = 559) whose success or failure were not yet known. Exhibit 7 shows the predicted 
success rates for each phase and for all phases combined. Confidence intervals are shown by the black bars, 
whereas orange tics show the weighted average of the success rates derived from an analysis of the related 
literature based on observations between 2000 and 2018 (see Exhibit 24 in the supplementary material A.4). 
Exhibit 7:Predicted success rates of current project pipeline 
The Exhibit shows the ML success ratio predicted for current pipeline projects split by  
phase and compares them to an average over literature estimates. 
 
Our predictions are slightly more optimistic than the average estimates of other independent research teams 
(clinical completion rates: 15.9% vs. 14.7%), in line with the increasing trend of drug approvals witnessed in 
recent years.14 Applying our project pipeline projections to a widely used R&D costing model15 suggests that the 
number of approvals in coming years will increase by 8.2% while the average cost of drug development will 
decrease by 3.9% . 
This example illustrates an important point: the use of the algorithm does not by itself change project outcomes. 
It only predicts them with higher accuracy than existing methods. In this case, its predictions coincidentally agree 
with the estimates of other researchers. In addition, however, the algorithm provides detailed project 
information that allows R&D managers to reshape their pipelines to improve future success rates, which they 
can do by divesting projects with poor predicted outcomes and redirecting resources toward more promising 
ones.  
For instance, Exhibit 8 shows that an orphan drug designation significantly boosts success rates over their 
expected average phase rates: +27 [+7] percentage points respectively for PII [PIII]; so do other expedited FDA 
review programs: +21% [+14%], MoA validated in a different indication: +17% [+13%]. If the molecule is already 
marketed in another indication, it boosts the success rate of a new indication by +22% [+22%] compared to 
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expected average values. Lastly, projects associated with higher clinical trial expenses are estimated more likely 
to succeed +14% [+3%].e 
 
Exhibit 8: Predicted success rate of current PII/PIII pipeline by success factors 
 
The Exhibit shows the success ratio predicted of current Phase II and III pipeline projects split various categories. The average 
predicted success ratios across projects are depicted by horizontal lines. The numbers in the text refer to the difference 
between predicted success ratio of a category and average predicted success ratio. 
 
Drug developers can also use the algorithm to study the impact of combinations of attributes and select the most 
desirable ones, or design better clinical research strategies. For example, the ML algorithm can be used to identify 
therapeutic areas and agents that offer better odds of clinical success. Exhibit 9 shows that these odds can vary 
considerably. In some instances small molecules or natural products seem to be less risky; in others, large 
molecule have the edge (see also Exhibit 25 and Exhibit 26 in the supplementary material A.4).  
 
 
 
 
 
 
eThe median clinical trial expense was estimated at $15 million for PII and $79 million for PIII. 
Exhibit 9: predicted phase II/III success rate per indication and technology 
Predicted success ratio Phase II Phase III 
Indication Small molecules 
Natural products 
Large 
molecules 
Small molecules 
Natural products 
Large 
molecules 
Hepatic & biliary 19.0% [58] - [8] - [6] - [1] 
Sensory organs 22.7% [44] 41.7% [36] 35.7% [14] - [7] 
Cancer 25.8% [690] 30.8% [464] 59.0% [83] 64.8% [88] 
Respiratory 28.6% [35] 33.3% [24] - [4] - [7] 
Blood 28.9% [38] 53.3% [30] 56.3% [16] 63.6% [11] 
Psychiatry 36.8% [57] - [0] 33.3% [15] - [0] 
Immunology 38.2% [34] 33.3% [51] 62.5% [16] 60.0% [20] 
Skin 41.1% [73] 45.8% [24] 92.9% [14] - [3] 
Urinary tract 42.1% [19] - [10] - [7] - [3] 
Diabetes 43.8% [32] 75.0% [12] - [10] - [3] 
Neurology 46.7% [120] 35.7% [28] 43.2% [44] - [9] 
Reproduction 50.0% [18] - - [8] - [1] 
Musculoskeletal 53.1% [32] 44.7% [47] 73.3% [15] 66.7% [18] 
Cardiovascular 56.8% [37] 45.2% [31] 40.0% [20] 41.7% [12] 
Gastro-intestinal 63.6% [44] 37.5% [16] - [10] - [8] 
Infections 66.2% [77] 32.4% [74] 61.8% [34] 45.5% [11] 
HIV & related  - [8] 28.6% [14] - [6] - [1] 
Averages 
36.3% 36.7% 57.8% 60.5% 
36.4% 58.9% 
Number of observations in brackets. Success rates are not calculated for cells with fewer than 10 observations. Average 
success rates are weighted by the number of projects 
5. Summary and discussion 
 
We have evaluated the performance of different machine-learning algorithms to predict the clinical success (or 
failure) of individual pharmaceutical projects as they progress through the various phases of clinical research. 
The predictions of our “best-in-class” ML algorithm are substantially more accurate than traditional methods 
based on historic success rates or discriminant analysis. When predicting the outcome of pipeline projects, the 
average of our individual predictions accords with the aggregate historical benchmarks from the literature. 
Our methodology closely adheres to good ML computational procedures, and additional steps were taken to 
control for the look-ahead bias, and filter out other potentially confounding factors such as drifts in the trends 
underpinning drug development, and the overweight influence of some indications. These robustness checks 
strengthen our findings and confirm the value of ML as a reliable predictor of clinical research outcomesf. Even 
though we abide by stringent quality standards, we should remain mindful that the algorithm may reproduce 
biases that can exist in the training set. Results should be inspected to detect such problem and corrective action 
be taken as appropriate. In other words, ML should inform the decision-making process of experts rather than 
replace it. 
The implications of our work are important for individual companies, the pharmaceutical industry and the entire 
biomedical research ecosystem. 
 
f Please consult supplementary material A.3 for more details on the robustness checks. 
Pharmaceutical companies can use our approach to improve the quality of their pipelines by directing their R&D 
investment towards projects whose attributes makes them more likely to succeed. The algorithm’s capability to 
predict phase outcomes at the individual project level gives them a powerful tool to reorder their R&D priorities, 
and significantly boost their R&D productivity by raising new drug output and reducing the number and cost of 
failed trials. 
At a higher level, our ML tool has the potential to change the industry’s risk profile. Over the decades, high risk 
has defined drug R&D. A handful of large companies has long dominated the industry because scale and staying 
power were required to survive high failure rates and the randomness of success. High prices and profitability 
were seen as necessary to withstand the devastating loss that a single failure could bring. Smaller companies 
found it difficult to develop enough new drugs to grow and rival their larger competitors. The ML demonstrated 
in this paper has the potential to change this. If risk is lower, more companies, especially smaller ones are likely 
to engage in drug R&D. If failures are fewer, less capital will be needed to succeed. That will stimulate 
entrepreneurial activity and cause the locus of innovation to gradually migrate from a handful of large companies 
to many smaller ones. The composition of innovation could also be affected since smaller, nimbler companies 
are more prone to explore new biology where high-value innovation has often been found. Scale and the 
resulting costs, risk-aversion, and bureaucracy could put large companies at a competitive disadvantage. The 
rationale for high prices will weaken and could evaporate. The result could be an industry that is more 
entrepreneurial, more productive, and cheaper. 
ML could also bring significant changes to the broader biomedical research ecosystem. It could divert resources 
away from some diseases and therapeutic areas that do not have the attributes they need to score well with the 
algorithm. This could happen, for instance, if the drug’s mode of action has not been validated, which is often 
the result of a poorly understood pathology. It would be a signal to policymakers and academic researchers to 
reorder their priorities and increase funding and focus on those areas where innovation is unlikely to flourish 
until knowledge gaps have been filled. The ecosystem will become smarter. It will have a tool to allocate 
resources where they are most needed in both basic and translational research. 
Lastly, this paper is another successful step in using ML to address challenges that, until now, have often been 
seen as intractable. BART had previously been used to address such challenges – for instance, the prediction of 
movie box-office revenues16. Here we apply it to predict the successes and failures in clinical development, a 
problem that long vexed the pharmaceutical industry, despite its capabilities and the obvious economic value of 
such tool. These successes raise hopes that further ML-driven breakthroughs are at hand. However, achieving 
them will require access to vast amounts of high-quality data to train algorithms – both positive data about 
successful experiments as well as negative data about failures. Assembling them will require extensive data-
sharing. Still, despite well-intended policies at funding organizations, there is concern that data-sharing at many 
organizations remains half-hearted17, 18. To reap the full societal benefits of ML, this needs to change. 
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Supplementary information A 
 
1. Data set characteristics 
 
Exhibit 10:description of candidate features used in ML algorithms 
 FEATURE NAME FEATURE DESCRIPTION 
P
R
O
D
U
C
T 
Product marketed Indicator. 1 if product is marketed for another indication before the phase 
status date 
Product failed Indicator. 1 if product has failed for another indication before the phase 
status date 
MoA validated Categorizes whether the MoA has been validated for the same indication, a 
different indication or has not been validated before the phase status date 
Product experience 
(count) 
Number of distinct indications in which the product was already active 
before the phase status date 
Patent duration Duration of elapsed patent life from filing date to phase status date 
Clinical trial cost Actual or estimated trial cost of the product as per EvaluatePharma 
Clinical trial results  Categorize clinical trial results: unavailable, partial, negative, mixed, or 
positive. Phase II results only used in PII, Phase III results only used in PIII 
Time in phase Time from start of the phase until phase status date.  
Patents cite Count of the distinct patent families that refer to the main patent of the 
product. as per Patstat database and merged to data set 
Patents cited Count of the citations of distinct patent families that the main patent of the 
product refers to. as per Patstat database and merged to data set 
Technology Categorizes the technology of the product used  
Product strategy Categorizes whether the product is developed in-house, via licensing, via 
company acquisition, product acquisition or joint venture 
Therapy type Categorizes whether the product has one or more active ingredients 
Companies per 
product 
Counts the number of companies involved in the development of the 
product 
IN
D
IC
A
TI
O
N
 
Market size 
(companies)  
Number of companies with marketed products for each indication 
Market size 
(products) 
Number of distinct marketed products for each indication 
Market inequality Standard deviation of product revenues (2017) for all marketed products in 
each indication 
Orphan drugs (count) Current number of marketed Orphan drugs for each indication 
Indication level 1 Indication category aggregated to different therapeutic areas 
Market success rate  The sum of marketed products over the sum of marketed withdrawn and 
abandoned products for each indication (comparable to ATC1) 
Phase time 
(indication) 
Phase specific median development time for each indication 
Phase success rate by 
indication 
Phase specific historic success rate by indication (comparable to ATC3) 
C
O
M
P
A
N
Y
 
Own similar products 
(count) 
Number of distinct similar products [similar products are products that rely 
on same technology] in which the company was active before the phase 
status date 
Market experience 
(count) 
Number of distinct products for the same indication, in which the company 
was active before the phase status date 
Time in market Number of months of a company’s experience in indication level 1 before 
the phase status date 
Own similar markets 
(count) 
Number of distinct similar markets [similar markets share the same 
indication level 1] in which the company was active before the phase status 
date 
R&D cost Research and development expenses of the company in the phase status 
year 
Company listed Indicator. 1 if company was publicly traded before the phase status date 
Company 
classification 
Categorizes companies in four distinct groups: Biotechnology, Global 
Majors, Regional Majors and Specialty 
Region Categorizes companies in regions based on their legal headquarter: Africa & 
Middle East, America ex USA, Asia & Oceania, Europe, USA 
R&D (count) Number of active R&D products of company 
Products (count) Number of marketed products of company 
Company success rate The sum of marketed products over the sum of withdrawn and abandoned 
products for each company 
R
EG
U
LA
TO
R
Y
 
A
N
D
 O
TH
ER
 Orphan status Indicator. 1 if the project is assigned orphan status in the US 
Expedited status Indicator. 1 if project is assigned expedited treatment by the FDA 
Phase success rate by 
MoA 
Phase specific historic success rate by mechanism of action (MoA) 
Phase success rate by 
tech 
Phase specific historic success rate by used product technology, such as 
biotechnology, vaccine or gene therapy 
The value of some features is status date dependent, meaning that its value reflects the information at the time of the “phase 
status date”, the date that determined the status of a project in a specific phase. For example, consider a project that is has 
failed in Phase III (labeled as success in PI and PII, but as failure in PIII). The “phase status date” in PIII would be the termination 
date. In PII, the “phase status date” is the date at which the success in Phase II is determined and since we do not observe the 
end date of Phase II in the data we approximate it by the start date of Phase III. Consequently, the “phase status date” in PI is 
the start date of Phase II.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Exhibit 11: Missingness analysis (missing features across data sets) 
  
  
  
The graphs visualize the missing features (light blue) for each observation in the data sets PI, PII and PIII are split according 
to whether the outcome of a project is known or is on-going. 
 
 
2. Machine learning routine and performance evaluation 
Machine learning methods used 
The fate of a pharmaceutical project as it passes through the various phases of clinical research depends on a 
combination of product-, company-, and market attributes. These attributes can be used by machine learning 
algorithms to predict the most likely outcome.  Since the performance of machine learning algorithms is highly 
data-dependent, we train eight different algorithms using training data from three sets of projects belonging to 
phase I, II, and III. We then evaluate the performance of the trained algorithms by analyzing their ability to 
discriminate between successful and failed projects when applied to three validation sets for phase I, II, and III. 
The eight ML algorithms span methods that are frequently used for prediction tasks, i.e., a simple decision tree 
(DT), boosted decision trees (C5.0)19, a random forest algorithm (RF)20, a Bayesian additive regression tree 
(BART)10,21, a support vector machine (SVM)22, an artificial neural network (ANN)23 a linear probabilistic 
regression (PROBIT), and an ensemble learner based on the three best performing methods. 
 
DT, C5.0, RF and BART are tree-based classification methods, which are suited to problems where non-linearities 
and interactions between features are plausible, but unknown. A classification tree can be thought of as a set of 
successive decision rules, called nodes. The branches, that extend from the nodes, split the observations 
according to these decision rules. At the terminal nodes each observation is categorized as either success or 
failure.  
The DT algorithm relies on only one tree while C5.0, RF and BART create an ensemble of trees but in different 
ways. The C5.0 method uses gradient boosting that enables the algorithm to learn from classification errors of 
prior trees; RF averages across estimates from multiple trees based on a random subset of features and projects; 
and BART sums the contribution of multiple trees. The structure of these trees depends on Bayesian priors that, 
to prevent overfitting of the model, are also applied on the error variance. The tree regularization achieved by 
the Bayesian approach combined with limiting the sum of trees acts as a natural way to prevent features from 
entering the model that add little explanatory power (i.e., in case of multicollinearity). Moreover, BART 
incorporates a Missingness-Incorporated-in-Attributes procedure (MIA)12, which expands the predictor space to 
include information on missing features (we elaborate on this below).  
The SVM algorithm, on the other hand, classifies observations by fitting a hyperplane to the dataset that divides 
it into predicted successes and failures. The hyperplane is supported by vectors which are chosen so that the 
overall distance (called the margin) between the hyperplane and the two classes is maximized along with the 
prediction accuracy. 
The ANN algorithm operates by constructing a network of nodes (called neurons), which are autonomous data-
processing units. The neurons are organized into three or more layers: an input layer that receives the input data, 
one or more downstream hidden layers, and an output layer that produces the predicted values. Each neuron 
receives incoming signals, processes them, and sends outgoing signals to other neurons. Each neuron processes 
incoming signals by using an activation function that resembles that of biological neurons, i.e., if the signal is 
below a threshold, it is not transmitted; if it is above, it is modulated according to a function that is characteristic 
of each neuron, and passed forward. During the iterative training process, the network receives pairs of actual 
input and output data. The input data is converted into signals by the neurons of the input layer. Those signals 
are sent to other neurons in downstream hidden layers which reprocess them and send them onward until they 
reach the output layer, where they are converted into output values. At each iteration, the modulation of each 
neuron’s signal is adjusted in a way that lessens the distance between the predicted and actual output value(s), 
thereby improving the quality of the prediction, until the training is completed. 
Next,, we train a standard linear regression PROBIT model to compare how classification performance changes, 
when outcomes are predicted by a linear combination of features without allowing for variable interactions. 
Lastly, we construct an ensemble learner based on a weighted average of the predictions of the three best 
performing methods. The weights are chosen via cross validation on part of the training set such that the linear 
combination of single predictions minimizes the prediction error. 
Machine learning training procedure 
Each of the three datasets is randomly split into a training set (70%) used to train the algorithms and a validation 
set (30%) used afterward to assess the performance of the trained algorithms. The validation set is not used until 
the training has been completed. Exhibit 12 sketches the training and validation procedure used in this paper. 
Before training the algorithms, we analyze whether pre-
processing the data improves predictive performance on 
the training set. Since missing data can negatively affect 
the performance of the trained algorithm, it is important 
to examine the volume of missing data and ways to 
mitigate it (see Exhibit 11 for a visual presentation of 
missingness across data sets). Applying Little’s tests to 
the feature space across data sets, allows us to clearly 
reject the Null hypothesis that missing data are randomly 
distributed24. There are many ways to handle missing 
data in input datasets. Here, we consider three 
approaches: a complete case (CC) analysis, in which 
features with more than 70% of missing values and all 
remaining observations that contain missing values are 
excluded, a nearest neighbor (NN) imputation algorithm, 
and an internal imputation (II) using directly the 
respective algorithm (not available for PROBIT, SVM and 
ANN). We set the number of neighbor observations 
considered in NN to 5 (5NN), since 5NN combined with 
RF achieves good classification performance in a similar setting5. Each training set is randomly split into a training 
set (70%) on which each algorithm is trained while successively applying each of the three missing value handling 
techniques. The trained algorithms are then evaluated on the remaining 30% of the training data by calculating 
the area under the receiver operating characteristic curve (AUC). This helps select the missing value handling 
technique that produces the highest AUC for each algorithm without involving the original validation dataset. In 
this case, the highest AUC is achieved by 5NN imputation for C5.0, PROBIT, SVM and ANN while the other 
algorithms are more accurate when using the internal missing value routines embedded in their software (see 
Exhibit 13). Missing input data values are imputed without considering their impact on the success classification, 
to prevent the imputed values from somehow reflecting this information. Training and validation datasets are 
imputed separately to avoid inducing any form of relation between them. 
After imputing missing values, we perform a feature selection step to keep excessive feature inclusion from 
degrading the predictive performance of the algorithms (e.g. by avoiding multicollinearity in selected features). 
We evaluate three feature selection methods: LASSO25, an oft-applied method that is based on the shrinkage of 
linear regression coefficients, RF_SE, an iterative variable elimination method used in RF and based on the 
smallest prediction loss26 and BART_IP that selects variables based on their inclusion proportion in a BART 
algorithm with a small number of trees13. After completing the imputation of the missing values, we use 70% of 
the training data to train each algorithm on each data set for each feature selection technique and compare the 
results based on the AUC from the 30% remaining training data (see Exhibit 14). For PROBIT, DT and ANN the 
RF_SE method performs best whereas LASSO is selected for SVM. The ensemble tree methods BART, RF and C5.0 
perform best without the use of an additional feature selection step. 
In a last step before the final validation, some algorithm hyperparameters are tuned using 5fold- cross validation 
on the complete training data for each data set. Hyperparameters tuned are the number of trees and the cut-off 
probability in BART, the number of randomly sampled variables at each split in RF, the number of boosting 
iterations in C5.0, the kernel shape of the distance measure in SVM and the number of hidden layers in ANN. We 
report the tuning results in Exhibit 15 to show that performance characteristics do not vary substantially across 
evaluated hyperparameter ranges. For each algorithm and data set we choose the hyperparameter specification 
that performed best. 
Exhibit 12: Applied training and testing routine 
Every algorithm is then trained on the full training dataset using the best performing missing value technique, 
feature selection criterion and adjusted hyperparameters. The trained algorithms are subsequently assessed 
using the validation data set that has been kept separate from the training procedure. To rule out that the test 
results are influenced by the random selection of the validation data, the entire training and validation procedure 
is repeated 100 times for each model and each data set and average performance measures are reported. 
 
Exhibit 13: Missing value imputation techniques by AUC across ML methods and data sets 
    PI PII PIII 
Complete Case (CC) 
BART 0.85 0.79 0.80 
RF 0.81 0.78 0.76 
C5.0 0.83 0.80 0.83 
SVM 0.84 0.78 0.76 
PROBIT 0.83 0.71 0.73 
ANN 0.49 0.54 0.49 
DT 0.34 0.65 0.29 
5 nearest neighbors (5NN)  
BART 0.82 0.89 0.79 
RF 0.82 0.90 0.82 
C5.0 0.84 0.89 0.78 
SVM 0.82 0.89 0.82 
PROBIT 0.82 0.87 0.77 
ANN 0.52 0.60 0.52 
DT 0.66 0.78 0.36 
Internal Imputation (II) 
BART 0.92 0.96 0.89 
RF 0.84 0.93 0.88 
C5.0 0.77 0.90 0.71 
SVM - - - 
PROBIT - - - 
ANN - - - 
DT 0.73 0.83 0.71 
The ML methods for which a missing value imputation method is selected are highlighted in bold.  
  
Exhibit 14: Feature selection techniques by AUC across ML methods and data sets 
Feature selection technique ML Method PI PII PIII 
LASSO 
BART 0.90 0.96 0.90 
RF 0.84 0.93 0.87 
C5.0 0.83 0.89 0.82 
SVM 0.83 0.89 0.83 
PROBIT 0.83 0.88 0.79 
ANN 0.82 0.85 0.76 
DT 0.74 0.84 0.71 
RF _ SE 
BART 0.89 0.94 0.89 
RF 0.84 0.92 0.86 
C5.0 0.81 0.88 0.82 
SVM 0.82 0.89 0.83 
PROBIT 0.83 0.88 0.84 
ANN 0.82 0.88 0.50 
DT 0.73 0.85 0.71 
BART_IP 
BART 0.90 0.95 0.91 
RF 0.85 0.92 0.87 
C5.0 0.75 0.88 0.81 
SVM 0.79 0.88 0.80 
PROBIT 0.78 0.88 0.81 
ANN 0.76 0.87 0.78 
DT 0.73 0.84 0.71 
No Feature selection 
BART 0.92 0.96 0.89 
RF 0.84 0.93 0.88 
C5.0 0.84 0.89 0.78 
SVM 0.82 0.89 0.82 
PROBIT 0.82 0.87 0.77 
ANN 0.52 0.60 0.52 
DT 0.73 0.83 0.71 
The ML methods for which a feature selection technique is selected are highlighted in bold.  
  
Exhibit 15 Average 5-fold cross validation results for tuning hyper parameters across algorithms 
 PI PII PIII 
Cutoff- prob rule class BART (Accuracy) 
0.3 0.829 0.881 0.856 
0.4 0.840 0.892 0.892 
0.5 0.848 0.903 0.879 
0.6 0.840 0.892 0.851 
0.7 0.817 0.867 0.792 
# trees    
50 0.850 0.899 0.875 
100 0.855 0.901 0.877 
150 0.859 0.900 0.870 
200 0.856 0.897 0.870 
# sampled variables RF (Accuracy) 
5 0.840 0.879 0.831 
6 0.835 0.879 0.838 
7 0.837 0.876 0.834 
8 0.841 0.876 0.824 
Boosting iterations C5.0 (Accuracy) 
10 0.793 0.847 0.795 
20 0.804 0.846 0.795 
30 0.807 0.850 0.806 
40 0.811 0.851 0.811 
50 0.811 0.852 0.813 
60 0.810 0.849 0.810 
70 0.812 0.850 0.800 
80 0.812 0.852 0.803 
90 0.814 0.851 0.803 
100 0.812 0.853 0.805 
Kernel shape SVM (AUC) 
linear 0.849 0.888 0.880 
polynomial 0.837 0.888 0.878 
radial  0.852 0.899 0.892 
sigmoid 0.839 0.892 0.886 
# hidden layers ANN (AUC) 
1 0.528 0.878 0.865 
2 0.720 0.874 0.857 
3 0.640 0.854 0.856 
4 0.718 0.878 0.856 
5 0.552 0.867 0.846 
6 0.691 0.867 0.844 
7 0.686 0.873 0.833 
8 0.665 0.878 0.809 
9 0.680 0.837 0.837 
10 0.573 0.859 0.834 
The hyperparameters that correspond to the highest performance for each phase (highlighted in bold) are chosen in the final 
training of the algorithms. 
 
 
Machine learning performance validation  
For all algorithms and data sets we report multiple performance features. The AUC measure is frequently used 
to report classification performance since its value is independent of the choice of a specific classification 
threshold.9 We report the average AUC together with the mean 95% confidence interval, calculated by the 
Delong method for each repetition individually and then averaged over all obtained upper and lower bounds.11 
The higher the AUC, the better the algorithm solves the trade-off between type I and type II prediction errors. 
An AUC of 0.5 indicates that a random outcome assignment would be equally predictive. An AUC of 1 indicates 
that there exists at least one classification threshold at which the model classifies each case correctly. Besides 
the AUC, the algorithm’s sensitivity (SENS, the number of correctly classified successes over the total number of 
true successes) and its specificity (SPEC, the number of correctly classified failures over the total number of true 
failures), the positive predictive value (PPV, the number of correctly classified successes over the total number 
of classified successes), the negative predictive value (NPV, the number of correctly classified failures over the 
total number of classified failures), the F1 score (F1, the harmonic mean between PPV and SENS), and the 
balanced accuracy (BACC, the geometric mean between SENS and SPEC) are reported in Exhibit 16. SENS, SPEC, 
PPV and NPV are intuitive performance measures stemming directly from the confusion matrix. The last two 
measures are useful to analyze in case the data is unbalanced in terms of outcomes. 
In all three data sets the BART algorithm achieves the highest classification performance with an average AUC of 
0.93 in PI, 0.96 in PII, and 0.94 in PIII. It also performs best in terms of F1 (0.90 PI, 0.86 PII, and 0.90 PIII) and BACC 
(0.83 PI, 0.89 PII, and 0.86 PIII) We therefore refer to this algorithm as `best-in-class’ in the main text and use it 
during subsequent analysis. RF shows a lower performance than BART for most measures apart from Sensitivity 
and NPV in PI and PIII.  Neither algorithm relies on additional feature selection or missing value imputation 
techniques, which makes them powerful stand-alone tools in our analysis. For C5.0 we find a slightly lower 
average AUC than for RF, followed by SVM. The performance of PROBIT is similar to SVM which shows that careful 
choice of missing value imputation and feature selection techniques can offset the linear restrictions imposed by 
this model. The worst performing methods in terms of average AUC and BACC are ANN and DT, presumably 
because in our application they were overfitting the data during the training phase. Lastly, the ensemble learner, 
constructed from optimally weighting the prediction values of BART, RF and C5.0 on the training set (Exhibit 17 
reports the weights), performs worse than the single BART algorithm in terms of AUC in PI and PII. Looking 
additionally at balanced performance measures such as F1 and BACC, the stand-alone BART method performs 
better across phases, which is why we selected it for the main part of our analysis. 
  
 Exhibit 16: Average validation results across ML algorithms and data sets 
ML 
Method 
Data 
set 
AUC 
Mean 
AUCL 
Mean 
AUCH 
Mean 
SENS 
Mean 
SPEC 
Mean 
PPV 
Mean 
NPV 
Mean 
F1 
Mean 
BACC 
Mean 
BART 
PI 0.93 0.92 0.95 0.91 0.76 0.89 0.80 0.90 0.83 
PII 0.96 0.95 0.97 0.82 0.95 0.90 0.91 0.86 0.89 
PIII 0.94 0.92 0.97 0.88 0.84 0.92 0.78 0.90 0.86 
RF 
PI 0.88 0.86 0.90 0.95 0.55 0.82 0.84 0.88 0.75 
PII 0.93 0.91 0.95 0.81 0.90 0.82 0.89 0.81 0.85 
PIII 0.91 0.87 0.94 0.94 0.61 0.83 0.83 0.88 0.77 
C 5.0 
PI 0.86 0.84 0.89 0.92 0.58 0.83 0.76 0.87 0.75 
PII 0.91 0.89 0.93 0.73 0.92 0.83 0.86 0.77 0.82 
PIII 0.88 0.84 0.92 0.88 0.67 0.85 0.74 0.86 0.78 
SVM 
PI 0.86 0.83 0.88 0.92 0.53 0.81 0.76 0.86 0.72 
PII 0.90 0.87 0.92 0.67 0.93 0.84 0.84 0.74 0.80 
PIII 0.87 0.82 0.91 0.91 0.61 0.83 0.77 0.86 0.76 
PROBIT 
PI 0.84 0.82 0.87 0.90 0.56 0.82 0.72 0.86 0.73 
PII 0.89 0.86 0.91 0.67 0.91 0.80 0.84 0.73 0.79 
PIII 0.83 0.78 0.88 0.88 0.55 0.80 0.71 0.83 0.71 
ANN 
PI 0.75 0.73 0.78 0.88 0.54 0.81 0.62 0.84 0.71 
PII 0.77 0.74 0.80 0.53 0.90 0.74 0.78 0.60 0.72 
PIII 0.82 0.77 0.87 0.88 0.59 0.82 0.70 0.84 0.73 
DT 
PI 0.69 0.66 0.72 0.92 0.44 0.78 0.71 0.84 0.68 
PII 0.85 0.82 0.88 0.60 0.91 0.78 0.80 0.67 0.75 
PIII 0.79 0.73 0.85 0.88 0.58 0.81 0.71 0.84 0.73 
Ensemble 
learner 
PI 0.93 0.91 0.95 0.92 0.72 0.87 0.82 0.89 0.82 
PII 0.91 0.88 0.94 0.84 0.85 0.75 0.91 0.79 0.85 
PIII 0.97 0.94 0.99 0.97 0.70 0.82 0.95 0.89 0.84 
Abbreviations: AUC - Area under the receiver operating characteristic curve; AUCL(H) - Lower (Upper) 95% AUC confidence 
interval calculated for each repetition based on DeLong method11; SENS: Sensitivity; SPEC: Specificity; PPV: Positive 
predictive value, NPV: Negative predictive value; F1: F1 Score; BACC: Balanced accuracy. Highlighted in bold are the values 
that correspond to the best performing algorithm for each phase. 
 
Exhibit 17: Weights of ensemble learner across data sets 
Ensemble learner 
weights 
Datasets 
PI PII PIII 
BART 0.77 0.49 0.86 
RF 0.23 0.05 0.14 
C 5.0 0.00 0.46 0.00 
The Exhibit shows for each data set the weights used by the ensemble learner 
 weighting the three best performing ML methods. 
  
 Discriminant analysis for feature selection and classification 
In practice, classification problems are often approached using methods whose input parameters relate linearly 
to outcomes, which we broadly refer to as discriminant analysis (DISCR). As one specific example of such a linear 
discriminant analysis, we implement a backward/forward probabilistic regression procedure with Bayesian 
information criterion and compare its classification performance on the validation set with that of BART in the 
main text. 
Bayesian information criterion (BIC) evaluates how well a model explains the data while staying as parsimonious 
as possible. The better this tradeoff gets solved by a model the higher is its BIC value. The procedure optimizes 
the BIC value by adding or removing features to a probabilistic regression, which means it finds the model that 
explains the data best without including too many parameters. The procedure stops when neither adding nor 
removing features contributes to the BIC of the model, thus keeping only the features with the highest 
explanatory power.  
We report the coefficients of the selected features, their standard errors and p-values in Exhibit 18, which 
complements the feature importance measures elicited by BART, because directionality and significance of 
effects are easily interpreted. Yet, one needs to bear in mind that the model is assumed to be linear in the effect 
of features on project outcome which might not be appropriate given its moderate predictive performance.  
During the validation task, the coefficients derived from running the DISCR model on the training set are applied 
to the input data of the validation set, resulting in classification values that can be compared to the true outcomes 
via various performance measures (see Exhibit 4 in main text) or classification plots (Exhibit 23 in the 
supplementary material A.4). 
 
 
 
 
Exhibit 18: Most important features based on backward/forward probabilistic regression
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Product Indication
Machine Learning for predicting project outcomes of the current pipeline 
When predicting project outcomes of the current pipeline, one cannot directly validate the resulting predictions. 
Therefore, it is crucial that the training set and the current pipeline share the same properties with respect to 
missing values and evaluated features. For on-going projects, feature information is on average better than for 
historical projects (even though information on some features such as clinical trial results is not fully available – 
see Exhibit 11), since for current projects an open data approach has been enforced.27 To rule out that the 
difference of missingness in the data influences prediction results, we first impute labeled and unlabeled data 
separately using a 5NN algorithm (see missing value imputation techniques above). We then train the BART 
algorithm and analyze the out-of-sample performance on the separately kept validation set (performance 
according to BACC: PI=76%, PII=81%, PIII=78%). Since the BART algorithm performs optimally when it imputes 
missing values internally, using 5NN to ensure that missingness between training and prediction data is 
comparable results in a slightly lower yet still advantageous classification performance compared to other 
methods. Next, the algorithm gets trained on the complete set of labeled data (see above) and is eventually used 
to predict outcomes of on-going projects. The results of this process are depicted in Exhibit 7, Exhibit 8, and 
Exhibit 9 of the main text and Exhibit 25, Exhibit 26 in the supplementary material A.4. 
 
3. Result robustness checks 
Even though our experimental set-up closely follows common ML procedures and the obtained project 
classification on validation sets seem very promising, we need to rule out that the reported results are driven by 
particularities in the data or the training/validation routine. We therefore perform various changes in the training 
and validation approach that aim at providing insights into the robustness of our validation results. 
 
Time series validation technique 
Randomly sampling training and validation sets from the data could lead to so called look-ahead bias, meaning 
that algorithms are trained on projects that happened later in time and thus learn from future information. To 
mitigate look-ahead bias we perform an additional time-series training and testing routine28 and compare its 
performance to our base results.  
To implement the time series validation technique, we train the algorithms on all projects whose status has been 
determined prior to year t and validate the performance using projects only in year t. Making sure to have enough 
observations in every training and testing set, the algorithms are first trained on all projects with determined 
outcome between 2009 and 2014, and then validated using projects whose outcome determined 2015 
(validation set is referred to as 2015). For the second (third) window, the algorithms are trained on projects 
determined between 2009 and 2015 (2009 and 2016) and validated on projects determined in 2016 (2017), and 
so on. 
We opt for this time series approach using multiple training and validation sets, to observe how the prediction 
quality of the ML methods shift over time. We compare its  prediction performance with the performance 
obtained from our base results (randomly splitting of data 100 times) using BACC (see Exhibit 19) and AUC (see 
Exhibit 20) on all algorithms except the ensemble learner (we feared that the data quantity would not be 
sufficient to learn the optimal weights on a separate training set). We find that the time series approach performs 
worse in PI, than the random sampling, which allows the conclusion that look-ahead bias is at least partly 
responsible for the classification results in PI. This is not surprising, since information on PI clinical trials are 
voluntarily disclosed which may induce some lags in information reporting of failed trials that are picked up by 
the algorithms using random sampling. In PII and PIII data sets, we do not detect signs of look-ahead bias when 
comparing the random sampling performance to the time series approach (AUC of BART in PI under random 
sampling: 93% vs. under mean AUC time series: 91%; PII 96% vs. 96% and PIII: 94% vs. 98%), i.e. splitting training 
and testing data according to a time dimension does not deliver worse results suggesting that look-ahead bias in 
PII and PIII data is less of a concern. 
 
 
 
Exhibit 19: Time series validation technique - algorithm performance according to balanced accuracy 
 PI  
  2015 2016 2017 2018 Mean  
BACC by 
Random Split  
BART 0.750 0.731 0.622 0.777 0.720 0.835 
RF 0.752 0.709 0.587 0.604 0.663 0.751 
C 5.0 0.779 0.760 0.638 0.687 0.716 0.750 
SVM 0.705 0.743 0.607 0.666 0.680 0.725 
PROBIT 0.749 0.674 0.576 0.850 0.712 0.730 
ANN 0.752 0.688 0.583 0.819 0.710 0.708 
DT 0.737 0.706 0.554 0.850 0.712 0.677 
  PII  
 2015 2016 2017 2018 Mean 
BACC by 
Random Split 
BART 0.852 0.932 0.903 0.859 0.887 0.886 
RF 0.685 0.756 0.877 0.741 0.765 0.853 
C 5.0 0.784 0.887 0.867 0.819 0.839 0.823 
SVM 0.755 0.892 0.850 0.809 0.827 0.799 
PROBIT 0.848 0.893 0.851 0.857 0.862 0.790 
ANN 0.859 0.910 0.830 0.847 0.861 0.716 
DT 0.789 0.711 0.764 0.853 0.779 0.751 
  PIII  
 
2015 2016 2017-2018 
Mean 
BACC by 
Random Split 
BART 0.786 0.798 0.931 0.838 0.862 
RF 0.786 0.688 0.810 0.761 0.772 
C 5.0 0.685 0.688 0.883 0.752 0.778 
SVM 0.628 0.594 0.905 0.709 0.759 
PROBIT 0.670 0.781 0.823 0.758 0.713 
ANN 0.670 0.704 0.918 0.764 0.734 
DT 0.798 0.721 0.858 0.793 0.727 
The table shows the BACC across algorithms using as validation set the projects of the year in the respective column and as 
training set the projects whose outcome was determined prior to that year. “Mean” denotes the average BACC across yearly 
testing sets. “BACC by Random Split” corresponds to the last column of Exhibit 16 to facilitate comparison.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Exhibit 20: Time series validation technique - algorithm performance according to AUC 
 PI  
  2015 2016 2017 2018 Mean  
AUC by 
Random Split  
BART 0.945 0.919 0.854 0.925 0.911 0.934 
RF 0.890 0.850 0.741 0.885 0.841 0.883 
C 5.0 0.936 0.906 0.806 0.851 0.875 0.864 
SVM 0.907 0.871 0.783 0.888 0.862 0.855 
PROBIT 0.850 0.829 0.674 0.883 0.809 0.843 
ANN 0.844 0.829 0.735 0.887 0.824 0.752 
DT 0.807 0.719 0.457 0.833 0.704 0.693 
  PII  
 2015 2016 2017 2018 Mean 
AUC by 
Random Split 
BART 0.965 0.977 0.965 0.949 0.964 0.960 
RF 0.913 0.942 0.948 0.825 0.907 0.926 
C 5.0 0.932 0.955 0.955 0.927 0.942 0.913 
SVM 0.927 0.972 0.950 0.933 0.945 0.897 
PROBIT 0.928 0.958 0.936 0.925 0.936 0.886 
ANN 0.924 0.970 0.890 0.891 0.919 0.770 
DT 0.900 0.859 0.457 0.833 0.762 0.850 
  PIII  
 
2015 2016 2017-2018 
Mean 
AUC by 
Random Split 
BART 0.971 0.977 0.978 0.975 0.944 
RF 0.937 0.901 0.944 0.927 0.908 
C 5.0 0.941 0.925 0.950 0.939 0.882 
SVM 0.924 0.918 0.983 0.942 0.866 
PROBIT 0.870 0.964 0.930 0.921 0.831 
ANN 0.916 0.929 0.970 0.938 0.821 
DT 0.840 0.870 0.927 0.879 0.791 
The table shows the AUC across algorithms using as validation set the projects of the year in the respective column and as 
training set the projects whose outcome was determined prior to that year. “Mean” denotes the average AUC across yearly 
testing sets. “AUC by Random Split” corresponds to the last column of Exhibit 16 to facilitate comparison.  
 
 
 
 
 
 
 
 
 
 
 
Performance on recent data only  
Since the drug development landscape changes over time, it might be useful to restrict the training/validation 
observations to the most recent projects. That way we guarantee that the algorithms are not trained on data, 
which contains information that might be outdated. Moreover, using only the most recent observations we avoid 
issues that relate to static project features (features that reflect information at the time the data was sourced 
rather than when the project outcome was determined – see Exhibit 10 for a description of features). This is a 
common problem when working with historical information dating back a few years, since much information was 
simply not digitalized and is now not possible to obtain ex-post.  
We train and validate each algorithm using data only on the two latest years limiting the issues discussed above 
while guaranteeing enough observations for the training and testing routine. The algorithms are used as specified 
previously (see section: in supplementary material A.2: Machine learning training procedure) and validation 
results are sampled 100 times randomly splitting the training/testing data at each run. We run the robustness 
check for each algorithm except the ensemble learner which would require additional training data to optimally 
select the weights of algorithm predictions. The performance of ML techniques on the reduced dataset using 
only recent data (see Exhibit 21) looks similar to the ones in Exhibit 16 (validation results using all data). BART is 
still the best performing methodology to be used for projects in phases II and III. As for phase I, C 5.0 performs 
best in terms of BACC but not AUC. All in all, we do not find any major differences in our results due to historical 
observations in our results and we confirm BART as our `best-in-class’ approach. 
 
Exhibit 21: Average validation results across ML algorithms and data sets – using only data of the two most recent years 
ML 
Method 
Data 
set 
AUC 
Mean 
AUCL 
Mean 
AUCH 
Mean 
SENS 
Mean 
SPEC 
Mean 
PPV 
Mean 
NPV 
Mean 
F1 
Mean 
BACC 
Mean 
BART 
PI 0.90 0.83 0.97 0.99 0.30 0.90 0.89 0.94 0.65 
PII 0.96 0.91 1.00 0.95 0.76 0.89 0.88 0.92 0.85 
PIII 0.99 0.97 1.00 0.97 0.90 0.95 0.94 0.96 0.94 
RF 
PI 0.84 0.73 0.94 0.99 0.35 0.90 0.85 0.94 0.67 
PII 0.91 0.84 0.98 0.96 0.58 0.83 0.89 0.89 0.77 
PIII 0.97 0.91 1.00 0.97 0.68 0.86 0.92 0.91 0.82 
C 5.0 
PI 0.85 0.76 0.94 0.97 0.43 0.91 0.73 0.94 0.70 
PII 0.92 0.86 0.99 0.92 0.74 0.88 0.83 0.90 0.83 
PIII 0.94 0.86 1.00 0.94 0.81 0.92 0.90 0.93 0.88 
SVM 
PI 0.81 0.71 0.92 1.00 0.20 0.88 0.91 0.94 0.60 
PII 0.94 0.88 0.99 0.92 0.76 0.89 0.83 0.90 0.84 
PIII 0.98 0.93 1.00 0.99 0.80 0.91 0.98 0.95 0.89 
PROBIT 
PI 0.74 0.61 0.86 0.95 0.23 0.85 0.72 0.90 0.59 
PII 0.75 0.69 0.81 0.73 0.61 0.73 0.63 0.73 0.67 
PIII 0.71 0.60 0.79 0.74 0.61 0.71 0.69 0.72 0.67 
ANN 
PI 0.63 0.54 0.73 0.97 0.26 0.90 0.57 0.94 0.62 
PII 0.87 0.78 0.96 0.85 0.71 0.86 0.71 0.85 0.78 
PIII 0.89 0.75 0.99 0.93 0.77 0.91 0.84 0.92 0.85 
DT 
PI 0.66 0.54 0.78 0.98 0.36 0.90 0.72 0.94 0.67 
PII 0.83 0.73 0.92 0.88 0.66 0.84 0.74 0.86 0.77 
PIII 0.85 0.70 0.97 0.90 0.70 0.86 0.78 0.87 0.80 
Abbreviations: AUC - Area under the receiver operating characteristic curve; AUCL(H) - Lower (Upper) 95% AUC confidence 
interval calculated for each repetition based on DeLong method11; SENS: Sensitivity; SPEC: Specificity; PPV: Positive 
predictive value, NPV: Negative predictive value; F1: F1 Score; BACC: Balanced accuracy. Highlighted in bold are the values 
that correspond to the best performing algorithm for each phase. 
 
 
Performance split by indication  
To detect whether the performance of the algorithms on the validation set is driven by certain subgroups of 
projects, we split the validation set based on therapeutic area and report the average AUC and average BACC for 
each area across ML methods and data sets (Exhibit 22). In line with the results from the complete validation 
sample, the BACC and AUC values of BART rank highest across therapeutic areas when compared to the other 
ML approaches. Moreover, we do not find substantial differences between the performance of different 
indication samples. But the outcome of projects from some indications seem to be predicted more accurate than 
of others. For example, PII Blood Cancer projects enjoy high classification properties across algorithms while the 
outcome of PII projects dealing with Cardiovascular diseases seems more challenging to classify correctly. Note 
we report only therapeutic areas for which occurrences in the validation set are sufficiently frequent (more than 
40 projects for PI and PII, more than 30 projects for PIII). 
Exhibit 22: ML performance on validation set split by indication 
 Average AUC  
  
  
BART RF C 5.0 SVM PROBIT ANN DT 
PI 
Skin 0.92 0.83 0.81 0.79 0.79 0.70 0.67 
Cardiovascular 0.92 0.85 0.83 0.83 0.83 0.72 0.72 
Neurology 0.91 0.86 0.86 0.85 0.84 0.76 0.77 
Infections 0.95 0.89 0.89 0.89 0.86 0.76 0.64 
Blood Cancer 0.92 0.88 0.84 0.82 0.80 0.73 0.53 
Solid tumour 0.93 0.89 0.86 0.85 0.83 0.75 0.69 
All indications 0.93 0.88 0.86 0.86 0.84 0.75 0.69 
PII 
Skin 0.96 0.90 0.86 0.84 0.84 0.73 0.80 
Cardiovascular 0.94 0.84 0.86 0.82 0.77 0.66 0.72 
Neurology 0.94 0.88 0.86 0.83 0.83 0.74 0.79 
Infections 0.94 0.89 0.90 0.90 0.88 0.77 0.82 
Blood Cancer 0.97 0.95 0.95 0.91 0.92 0.78 0.88 
Solid tumour 0.96 0.94 0.92 0.90 0.90 0.77 0.84 
All indications 0.96 0.93 0.91 0.90 0.89 0.77 0.85 
PIII 
Infections 0.91 0.87 0.84 0.79 0.76 0.74 0.69 
Solid tumour 0.96 0.92 0.93 0.92 0.87 0.87 0.81 
All indications 0.94 0.91 0.88 0.87 0.83 0.82 0.79 
    Average BACC 
PI Skin 0.76 0.66 0.68 0.66 0.66 0.64 0.61 
  Cardiovascular 0.79 0.69 0.71 0.71 0.71 0.70 0.69 
  Neurology 0.82 0.73 0.76 0.74 0.72 0.71 0.71 
  Infections 0.85 0.74 0.76 0.73 0.69 0.71 0.66 
  Blood Cancer 0.81 0.75 0.72 0.66 0.69 0.68 0.61 
  Solid tumour 0.84 0.79 0.75 0.73 0.73 0.71 0.68 
  All indications 0.83 0.75 0.75 0.72 0.73 0.71 0.68 
PII Skin 0.91 0.84 0.78 0.77 0.77 0.69 0.70 
  Cardiovascular 0.86 0.76 0.77 0.72 0.68 0.61 0.65 
  Neurology 0.84 0.81 0.77 0.73 0.73 0.69 0.70 
  Infections 0.85 0.82 0.82 0.80 0.80 0.71 0.74 
  Blood Cancer 0.92 0.87 0.86 0.82 0.80 0.72 0.81 
  Solid tumour 0.88 0.87 0.83 0.78 0.77 0.71 0.73 
  All indications 0.89 0.85 0.82 0.80 0.79 0.72 0.75 
PIII Infections 0.75 0.66 0.69 0.68 0.67 0.66 0.65 
  Solid tumour 0.88 0.85 0.86 0.83 0.78 0.78 0.76 
  All indications 0.86 0.77 0.78 0.76 0.71 0.73 0.73 
 
 
4. Extra graphics and tables 
The Exhibit shows for each phase the estimated success probabilities for failed and successful projects in the validation 
set using the BART method (red dots) and the discriminant method (grey dots). For each category, the estimated average 
success probability is depicted by horizontal lines. On average, the estimated success probability of successful (failed) 
projects is estimated higher (lower) using BART in comparison to DISCR.  
 
Exhibit 24: Analysis of the related literature regarding the estimation of phase success rates 
Source 
Sample 
Size 
Time  
Success rates 
in  
Phase I 
in  
Phase II 
 in  
Phase III 
Clinical Completion  
(Phase I-Phase III) 
Wong and Lo (2019)3  15102 2000-2015 66.4% 48.6% 59.0% 19% 
EvaluatePharma (2018)29  16000 2000-2018 66.8% 33.1% 57.5% 13% 
Thomas et al. (2016)30 7455 2006-2015 63.2% 30.7% 58.1% 11% 
Hay et al. (2014)31 4451 2003-2011 64.5% 32.4% 60.1% 13% 
DiMasi (2014)32 1442 1995-2007 59.5% 35.5% 62.0% 13% 
DiMasi et al. (2010)33 1738 1993-2004 71.0% 45.0% 64.0% 20% 
Abrantes-Metz et al. (2004)34 2328 1989-2002 80.7% 57.7% 56.7% 26.4% 
Weighted average reported 
in main text (source 1-4)  2000-2018 65.8% 38.1% 58.4% 14.7% 
We calculate the average phase success rates using only the first four sources of our literature review which are based on 
estimates from more recent time periods (2000-2018) and are therefore better suited to compare to our estimations. The 
weights of the average are based on the sample size of each contribution. 
Exhibit 23:ML and discriminant analysis classification values separated by phase and true outcome 
Exhibit 25 Predicted success rates of current PII/PIII pipeline by technology 
 
  
Exhibit 26: Predicted success rates of current PII/PIII pipeline by indication 
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